University of Strathclyde
Investigating the immunomodulatory effects of Non-Ionic Surfactant Vesicles to combat viral sepsis
Abstract
dc:description.abstractCurrent anti-inflammatory therapies often utilise a single mechanism of action and come witha range of side-effects that reduce the scope of therapeutic applications. One such therapyis the conventional corticosteroid, dexamethasone used to treat the hyperinflammatoryresponse-induced sepsis associated with severe SARS-CoV-2 infection. This drug hasdisplayed poor efficacy in early stages of SARS-CoV-2 infection, alongside side effects suchas weight gain, mood changes, vision impairment, osteoporosis, and poor glycaemic controlin diabetic patients - a cohort at greater risk of death from SARS-CoV-2 infection. Herein, Iexplore Non-Ionic Surfactant Vesicles (NISV) as an immunomodulatory therapy for thetreatment of viral infection induced sepsis. I compare NISV and dexamethasone byexamining modulation of cytokine production in TLR7 and TLR8 stimulated bone marrowderived macrophages (BMDM) using ELISA and Cytometric bead array, alongsidetranscriptomic and metabolomic analyses. I also investigate NISV size as a factor in theirimmunomodulatory effects. I demonstrate that whilst dexamethasone displays broadimmunosuppression of cytokines regardless of TLR stimulation, NISV differentially modulatecytokine production dependent on specific TLR activation. This effect is generally retained asNISV size decreases, with a small increase in potency. Whilst NISV effects on energymetabolism are minor, I observe an increase in phospholipid synthesis and regulation of theanti-inflammatory TCA cycle metabolite itaconate in treated cells. Finally, I demonstrate thatwhilst both NISV and dexamethasone downregulate NF-kB activation, NISV also controlinflammation through downregulation of the non-canonical NLRP3 inflammasome. Here, Ibroadly present NISV as an immunomodulatory therapy that can transcriptionally regulateinflammation-associated gene expression through multiple regulatory pathways in a way thatdexamethasone cannot. These results support further investigation of NISV as analternative anti-inflammatory to widely used corticosteroids during virally induced sepsis.
Degree
thesis:*- Name dc:type.qualificationname
- phd
- Level dc:type.qualificationlevel
- doctoral-pg
- Grantor dc:publisher.institution
- University of Strathclyde
- Year dc:date.issued
- 2024
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- MacKie, Logan
- Advisor dc:contributor.advisor
-
- Roberts, Craig
- Author Identifier dc:creator.authoridentifier
-
- 202061198
Rights
- Licence dc:rights.uri
Identifiers
dc:identifier.*- Identifier
- T16893